{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["44(1)"],"submitter":["He YF"],"pubmed_abstract":["TPN171 is a novel phosphodiesterase-5 (PDE5) inhibitor used to treat pulmonary arterial hypertension (PAH) and erectile dysfunction (ED), which currently is undergoing phase II clinical trials in China. In this single-center, single-dose, nonrandomized, and open design study, radiolabeled [<sup>14</sup>C]TPN171 was used to investigate the metabolic mechanism, pharmacokinetic characteristics, and clearance pathways of TPN171 in 6 healthy Chinese male volunteers. Each volunteer was administered a single oral suspension of 10 mg (100 μCi) of [<sup>14</sup>C]TPN171. We found that TPN171 was absorbed rapidly in humans with a peak time (T<sub>max</sub>) of 0.667 h and a half-life (t<sub>1/2</sub>) of approximately 9.89 h in plasma. Excretion of radiopharmaceutical-related components was collecte"],"journal":["Acta pharmacologica Sinica"],"pagination":["221-233"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9813128"],"repository":["biostudies-literature"],"pubmed_title":["Pharmacokinetics, mass balance, and metabolism of [<sup>14</sup>C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension."],"pmcid":["PMC9813128"],"pubmed_authors":["Yu CY","Yang FP","Yao XM","Liu Y","Liu YM","Duan HQ","Diao XX","He YF","Yu C","Shen JS","Liu GY","Yu JH","Cheng H","Wang Z","Odilov A","Tian GH"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacokinetics, mass balance, and metabolism of [<sup>14</sup>C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension.","description":"TPN171 is a novel phosphodiesterase-5 (PDE5) inhibitor used to treat pulmonary arterial hypertension (PAH) and erectile dysfunction (ED), which currently is undergoing phase II clinical trials in China. In this single-center, single-dose, nonrandomized, and open design study, radiolabeled [<sup>14</sup>C]TPN171 was used to investigate the metabolic mechanism, pharmacokinetic characteristics, and clearance pathways of TPN171 in 6 healthy Chinese male volunteers. Each volunteer was administered a single oral suspension of 10 mg (100 μCi) of [<sup>14</sup>C]TPN171. We found that TPN171 was absorbed rapidly in humans with a peak time (T<sub>max</sub>) of 0.667 h and a half-life (t<sub>1/2</sub>) of approximately 9.89 h in plasma. Excretion of radiopharmaceutical-related components was collecte","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-04-29T02:25:25.025Z","creation":"2025-04-20T09:26:30.522Z"},"accession":"S-EPMC9813128","cross_references":{"pubmed":["35676531"],"doi":["10.1038/s41401-022-00922-6"]}}